Filing Flows › Biocryst Pharmaceuticals (BCRX) › Guidance & outlook
Biocryst Pharmaceuticals (BCRX) guidance and outlook
Biocryst Pharmaceuticals (BCRX) raised its guidance on Nov 4, 2026: Revenue $715M–$730M for FY2026. Biocryst Pharmaceuticals' 10-Q filed Nov 4, 2026 makes 13 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $625M–$645M | reaffirmed |
| Revenue | FY2026 | $715M–$730M | raised |
| Stock-based compensation | FY2026 | $415M–$425M | new |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- Our business strategy includes leveraging this established commercial platform to successfully commercialize a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics targeting a range of rare diseases.
- We monitor and analyze this data on an ongoing basis as we continue to commercialize ORLADEYO and adjust our forecasts accordingly.
- Due to the foregoing factors, it is possible that our operating results will be below the expectations of market analysts and investors.
- The SAB will provide independent scientific and strategic guidance as we aim to advance our research and development strategy and build a high value novel drug pipeline.
- We intend to contain costs and cash flow requirements by closely managing our third-party costs and headcount, leasing our facilities, and contracting with other parties to conduct certain research and development projects.
- Our liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of our products and the future progression of our product candidates.
- To the extent there are material differences between these estimates and actual results, our consolidated financial statements will be affected.
- We consider facts and circumstances known to us at the time, which may include assumptions regarding expected patient enrollment, site activation and estimated project duration.
- In expensing service fees, we estimate the time period over which services will be performed and the level of effort expended in each period.
- We reassess the expected royalty payments each reporting period and account for any changes through adjustments to the effective interest rates on a prospective basis.
- The assumptions used in determining the expected repayment terms of the debt and amortization periods of the issuance costs requires that we make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized.
- The valuation allowance is based on estimates of future earnings in each of the jurisdictions in which we operate and the period over which our deferred tax assets will be recoverable.
Biocryst Pharmaceuticals' latest quarter
Biocryst Pharmaceuticals, Q3 2026: revenue $180M (+13% year over year), operating margin 29.6%, net earnings $37.9M, operating cash flow $33.0M. The chart follows the revenue to costs, profit and cash.
Questions
Did Biocryst Pharmaceuticals raise or lower its guidance?
Biocryst Pharmaceuticals (BCRX) raised its guidance on Nov 4, 2026: Revenue $715M–$730M for FY2026.
What does Biocryst Pharmaceuticals expect?
Our business strategy includes leveraging this established commercial platform to successfully commercialize a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics targeting a range of rare diseases. We monitor and analyze this data on an ongoing basis as we continue to commercialize ORLADEYO and adjust our forecasts accordingly. Due to the foregoing factors, it is possible that our operating results will be below the expectations of market analysts and investors.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.